- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942961
Evaluation of a Values-Clarification Tool for Older Adults With Cancer
This randomized pilot study will evaluate whether a decision support tool can improve values clarification and shared decision-making (SDM) among older adults with advanced-stage cancer. The tool, developed previously, helps patients identify their personal values and provides tailored feedback and relevant questions to support treatment discussions. Participants will be randomly assigned to intervention or control groups and take part in simulated patient-clinician consultations. The study aims to assess and compare the quality of values clarification and SDM processes between the two groups.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill, Department of Radiation Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
- Subjects is willing and able to comply with study procedures based on the judgement of the investigator.
- Age is 60 years or above at the time of consent (patients).
- Current or previous cancer diagnosis at advanced stage, not limited by site.
Exclusion Criteria:
- Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
Participants assigned to the intervention group will receive the values-clarification decision support tool, which guides them in identifying their personal values, preferences, and priorities regarding cancer treatment. The tool also provides tailored feedback and relevant questions to help participants communicate their preferences and support discussions with the clinician during simulated consultations. |
Participants assigned to the intervention group will receive a decision support tool designed for older adults with advanced-stage cancer. The tool helps participants identify and clarify their personal values, preferences, and priorities regarding cancer treatment. It also provides tailored feedback and relevant questions from question prompt lists (QPLs) to support communication and shared decision-making during simulated clinical consultations. |
|
Active Comparator: Control group
Participants receive contextualized cancer-related educational information from the American Cancer Society and do not receive the values-clarification decision support tool. |
Participants will receive contextualized cancer-related educational information from the American Cancer Society. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Values Clarification
Time Frame: Baseline, Up to 1 hour
|
The primary endpoint is the quality of values-clarification processes during simulated clinical consultations, measured using a standardized checklist developed by the study team. Checklist scores will range from 0 to 100, with higher scores indicating better quality of values clarification. Scores will be compared between participants who receive the values-clarification decision support tool (intervention group) and those who receive American Cancer Society educational information (control group), overall and stratified by consultation type (values-based and non-values-based). Higher scores indicate better quality. |
Baseline, Up to 1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants' Perceptions of the Decision Support Tool and Shared Decision-Making
Time Frame: Baseline, Up to 1 hour
|
Participants' perceptions will be assessed through semi-structured interviews and questionnaires to evaluate: (1) their experiences and perceptions of receiving tailored feedback and content-matched questions based on their stated values; (2) their perceptions of the values-clarification process; and (3) their perceptions of shared decision-making (SDM) during simulated clinical consultations. |
Baseline, Up to 1 hour
|
Collaborators and Investigators
Investigators
- Principal Investigator: Daniel R Richardson, MD, MA, MSc, UNC Lineberger Comprehensive Cancer Center
Publications and helpful links
Helpful Links
- <p>University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials</p>
- <p>Advancing Knowledge of Values-Clarification Processes During Complex Decision-Making Among Older Adults With Advanced Cancer: Protocol for a Pilot Randomized Trial Using Simulated Patient-Clinician Encounters</p>
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC2331
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.